Economic optimization of a global strategy to address the pandemic threat J Pike, T Bogich, S Elwood, DC Finnoff, P Daszak Proceedings of the National Academy of Sciences 111 (52), 18519-18523, 2014 | 204 | 2014 |
Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review J Pike, SD Grosse Applied health economics and health policy 16 (6), 765-778, 2018 | 195 | 2018 |
Decline in COVID-19 hospitalization growth rates associated with statewide mask mandates—10 states, March–October 2020 H Joo MMWR. Morbidity and Mortality Weekly Report 70, 2021 | 80 | 2021 |
Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations SD Grosse, KV Krueger, J Pike Journal of medical economics 22 (6), 501-508, 2019 | 72 | 2019 |
Quantifying family spillover effects in economic evaluations: measurement and valuation of informal care time SD Grosse, J Pike, R Soelaeman, JM Tilford Pharmacoeconomics 37 (4), 461-473, 2019 | 69 | 2019 |
Recommendations of the second panel on cost effectiveness in health and medicine: a reference, not a rule book C Carias, HW Chesson, SD Grosse, R Li, MI Meltzer, GF Miller, ... American journal of preventive medicine 54 (4), 600-602, 2018 | 46 | 2018 |
A review of measles outbreak cost estimates from the United States in the postelimination era (2004–2017): estimates by perspective and cost type J Pike, AJ Leidner, PA Gastañaduy Clinical Infectious Diseases 71 (6), 1568-1576, 2020 | 40 | 2020 |
Peer Reviewed: Direct Medical Costs Associated With Post–COVID-19 Conditions Among Privately Insured Children and Adults J Pike, L Kompaniyets, MC Lindley, S Saydah, G Miller Preventing chronic disease 20, 2023 | 28 | 2023 |
Societal costs of a measles outbreak J Pike, A Melnick, PA Gastañaduy, M Kay, J Harbison, AJ Leidner, S Rice, ... Pediatrics 147 (4), 2021 | 24 | 2021 |
Catastrophic risk: waking up to the reality of a pandemic? J Pike, JF Shogren, D Aadland, WK Viscusi, D Finnoff, A Skiba, P Daszak EcoHealth 17, 217-221, 2020 | 18 | 2020 |
Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits–United States, April 2020–December 2020 AR Board, S Kim, J Park, L Schieber, GF Miller, J Pike, LJ Cremer, ... Drug and Alcohol Dependence 232, 109297, 2022 | 14 | 2022 |
A Discrete Choice Analysis Comparing COVID-19 Vaccination Decisions for Children and Adults LA Prosser, AL Wagner, E Wittenberg, BJ Zikmund-Fisher, AM Rose, ... JAMA Network Open 6 (1), e2253582-e2253582, 2023 | 11 | 2023 |
Cost of a measles outbreak in a remote island economy: 2014 Federated States of Micronesia measles outbreak J Pike, A Tippins, M Nyaku, M Eckert, L Helgenberger, JM Underwood Vaccine 35 (43), 5905-5911, 2017 | 11 | 2017 |
2016–2017 Arkansas mumps outbreak in a close-knit community: assessment of the economic impact and response strategies J Pike, M Marin, A Guo, D Haselow, H Safi, F Zhou Vaccine 38 (6), 1481-1485, 2020 | 7 | 2020 |
Patient flow time data of COVID-19 vaccination clinics in 23 sites, United States, April and May 2021 BH Cho, HM Athar, LG Bates, BO Yarnoff, LTQ Harris, ML Washington, ... Vaccine 41 (3), 750-755, 2023 | 5 | 2023 |
Cost-effectiveness of pediatric norovirus vaccination in daycare settings LN Steimle, J Havumaki, MC Eisenberg, JNS Eisenberg, LA Prosser, ... Vaccine 39 (15), 2133-2145, 2021 | 5 | 2021 |
Cost of responding to the 2017 University of Washington mumps outbreak: a prospective analysis J Pike, S Schwartz, M Kay, A Perez-Osorio, M Marin, M Jenkins, J Routh, ... Journal of Public Health Management and Practice 26 (2), 116-123, 2020 | 5 | 2020 |
Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012–2016 J Pike, AJ Leidner, JR MacNeil, AC Cohn Vaccine 37 (1), 7-10, 2019 | 5 | 2019 |
Cost-effectiveness analysis of vaccination with recombinant zoster vaccine among hematopoietic cell transplant recipients and persons with other immunocompromising conditions … AJ Leidner, TC Anderson, K Hong, IR Ortega-Sanchez, A Guo, J Pike, ... Value in Health 26 (2), 204-215, 2023 | 4 | 2023 |
Cost-effectiveness of nirsevimab for respiratory syncytial virus in infants and young children DW Hutton, LA Prosser, AM Rose, K Mercon, IR Ortega-Sanchez, ... Pediatrics 154 (6), 2024 | 3 | 2024 |